| Literature DB >> 34095316 |
Fan Zhang1,2, Meiyun Zhou1, Shuangshuang Li1, Jinhua Gu3, Yuanyuan Qian1, Sisi He1, Li Hong1, Linlin Sun3, Xiaohua Zhang1, Weigang Ji1.
Abstract
Bioactive peptides attract growing concerns for their participation in multiple biological processes. Their roles in the pathogenesis of type 1 diabetes mellitus remain poorly understood. In this study, we used LC-MS/MS technology to compare the peptide profiling between pancreatic tissue of T1DM mice and pancreatic tissue of matched control groups. A total of 106 peptides were differentially expressed in T1DM pancreatic tissue, including 43 upregulated and 63 downregulated peptides. Most of the precursor proteins are insulin. Further bioinformatics analysis (GO and pathway analysis) indicated that the potential functions of these differential peptides were tightly related to regulation of endoplasmic reticulum stress. In conclusion, this study highlights new candidate peptides and provides a new perspective for exploring T1DM pathogenesis and clinical treatments.Entities:
Year: 2021 PMID: 34095316 PMCID: PMC8164536 DOI: 10.1155/2021/9987042
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Differently expressed peptides between T1DM and normal mice. (a) Of the 1,063 nonredundant peptides, 106 peptides were significantly differentially expressed in the T1DM mice (fold change ≥ 1.2 and p < 0.05), including 43 upregulated and 63 downregulated peptides. Hierarchical clustering showed significant differences in expression between the two groups. The twenty upregulated (b) and downregulated (c) peptides with the highest fold changes were displayed. N: control; T1DM: type 1 diabetes mellitus; high expression: red; low expression: green.
Figure 2Characteristics of differentially expressed peptides: (a) amino acid of peptides; (b) molecular weight (MW); (c) isoelectric point (pI); (d) scatter plot of MW versus pI; (e) peptides shared the same precursor proteins; (f) cleavage method of peptide; (g) four cleavage sites in downregulated peptides; (h) four cleavage sites in upregulated peptides.
Differentially expressed peptides located in function domain based on Uniport and Pfam database.
| Protein | Peptide sequence | Location | Domain location | Domain description |
|---|---|---|---|---|
| Downregulated peptides | ||||
| PDIA2 | VDGPAEPELT | 103-112 | 29-155 | Thioredoxin 1 |
| INS1 | ELGGSPGDL | 67-75 | 28-107 | Insulin |
| INS1 | ELGGSPGDLQTLA | 67-79 | 28-107 | Insulin |
| INS2 | GAGDLQTLAL | 73-82 | 28-109 | Insulin |
| AMY2 | QNDWIGPPN | 366-374 | 26-410 | Aamy |
| INS2 | DPQVAQLELGGGPGAGDLQT | 60-79 | 28-109 | Insulin |
| INS2 | ELGGGPGAGDLQT | 67-79 | 28-109 | Insulin |
| INS2 | LELGGGPGAGDLQT | 66-79 | 28-109 | Insulin |
| INS2 | VEDPQVAQLELGGGPGAGDLQT | 58-79 | 28-109 | Insulin |
| INS2 | ELGGGPGAGDLQTL | 67-80 | 28-109 | Insulin |
| NUPR1 | EAAANTNRPSPGGHE | 49-63 | 21-77 | Phospho-p8 |
| IAPP | SSNNLGPVLPPTNVGSNTY | 56-74 | 29-79 | Calcitonin |
| INS2 | EDPQVAQLELGGGPGAGDLQ | 59-78 | 28-109 | Insulin |
| INS2 | EDPQVAQLELGGGPGAGDLQT | 59-79 | 28-109 | Insulin |
| INS2 | VEDPQVAQLELGGGPGAGDLQ | 58-78 | 28-109 | Insulin |
| INS2 | ELGGGPGAGDLQ | 67-78 | 28-109 | Insulin |
| INS1 | EVEDPQVEQLELGGSPGD | 57-74 | 28-107 | Insulin |
| Hbbt1 | LLVVYPWTQR | 36-45 | 2-251 | Globin |
| INS2 | VEDPQVAQLELGGGPGAGD | 58-76 | 28-109 | Insulin |
| INS2 | EDPQVAQLELGGGP | 59-72 | 28-109 | Insulin |
| INS2 | QLELGGGP | 65-72 | 28-109 | Insulin |
| INS2 | EDPQVAQLELGGGPGAGD | 59-76 | 28-109 | Insulin |
| INS2 | GGPGAGDLQTL | 70-80 | 28-109 | Insulin |
| Eif4a1 | NTSIEEMPLN | 392-401 | 245-406 | Helicase C-terminal |
| UB2L3 | VNDPQPEHPL | 112-121 | 2-149 | UBC core |
| Rplp0 | ADPSAFAAAAPA | 275-281 | 231-316 | Ribosomal-60s |
| INS2 | QLELGGGPGAGDL | 65-77 | 28-109 | Insulin |
| INS2 | LGGGPGAGDL | 68-77 | 28-109 | Insulin |
| INS2 | GGGPGAGDLQT | 69-79 | 28-109 | Insulin |
| Actb | VAPEEHPVLLTEAPLNPK | 96-113 | 2-375 | Actin |
| IAPP | GPVLPPTNVGSNTY | 61-74 | 29-79 | Calcitonin |
| INS2 | ELGGGPGAGDL | 67-77 | 28-109 | Insulin |
| AMY2 | LNPNNREFPAVP | 134-145 | 26-410 | Aamy |
| Ruvbl1 | AQTEGINISEEALNHLGEIGTK | 379-400 | 374-439 | TIP49-c |
| MDH1 | GVISDGNSYGVPDD | 270-283 | 156-331 | Ldh_1_N |
| B2m | AHTEFTPTETDT | 86-97 | 25-114 | Ig-like |
| Upregulated peptides | ||||
| Actb | DIAALVVDN | 4-12 | 2-375 | Actin |
| Rpsa | APTAQATEWVGATTE | 279-293 | 202-295 | 40S_SA_C |
| Hsp90b1 | SLTDENALAGNEELT | 119-133 | 96-255 | HATPase-c |
| Tuba1a | DLEPTVIDEVRTGT | 69-82 | 3-214 | Tubulin |
| Rbm3 | DYSGRSQGGYD | 131-141 | 81-154 | Disordered |
| Cct7 | GVDINNENIADN | 476-487 | 32-524 | Cpn60_TCP1 |
| ERP27 | DLEIPIVS | 66-73 | 39-152 | Thioredoxin |
| UBN2 | DETDPFIDNSEA | 196-207 | 180-231 | HUN |
| Ptma | SDAAVDTSSEITTKD | 62-76 | 62-170 | Prothymosin |
| AMY2 | SAEDPFIAIHADS | 494-506 | 419-507 | Aamy_C |
| Atp5f1b | EVAQHLGES | 98-106 | 63-129 | ATP-synt_ab_N |
| P4hb | DRTVIDYNGE | 453-462 | 348-477 | Thioredoxin |
Figure 3Gene Ontology (GO) and pathway analysis of these precursor proteins: (a) cellular components; (b) molecular functions; (c) biological processes; (d) pathway analysis.
Figure 4Functional clustering by IPA. (a) Network analysis of “cancer, endocrine system disorders, organismal injury and abnormalities”. (b) Network analysis of “carbohydrate metabolism, cell death and survival, skeletal and muscular disorders” (upregulation, red; downregulation, green). (c) The top twenty precursor proteins related disease function.